Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd (SPARC) last traded at ₹194, a market capitalisation of ₹6,284 crore, on a P/E of 3.96. Over the past 52 weeks the stock has ranged between ₹108 and ₹289. Sun Pharma Advanced Research Company Ltd last reported results for the quarter ended Jun 2026, with sales of ₹40 crore and net profit of ₹-21 crore. Figures are as of 25 Aug 2026 and are not real time.
Sun Pharma Advanced Research Company Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Sun Pharma Advanced Research Company Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹40 cr, up 300.0% from ₹10 cr a year earlier. Net profit was ₹-21 cr, up 59.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | 40 |
| Expenses | 116 | 89 | 80 | 62 | 74 | 65 | 80 | 74 |
| Operating profit | -103 | -74 | -53 | -52 | -66 | -57 | 1,773 | -34 |
| OPM % | -800% | -494% | -196% | -540% | -836% | -670% | 96% | -85% |
| Other income | 0 | 0 | 0 | 9 | 0 | -12 | 2 | 24 |
| Interest | 1 | 3 | 5 | 6 | 8 | 9 | 12 | 8 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| Profit before tax | -107 | -79 | -61 | -52 | -76 | -80 | 1,761 | -21 |
| Tax % | 0% | 0% | -1% | 0% | 0% | 0% | -0% | 1% |
| Net profit | -107 | -80 | -60 | -52 | -76 | -80 | 1,761 | -21 |
| EPS (₹) | -3.31 | -2.45 | -1.84 | -1.60 | -2.34 | -2.48 | 54.27 | -0.64 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sun Pharma Advanced Research Company Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 239 | 76 | 72 | 1,879 | 1,909 |
| Operating profit | -214 | -402 | -323 | 1,599 | 1,617 |
| OPM % | -90% | -532% | -450% | 85% | 85% |
| Net profit | -223 | -387 | -343 | 1,553 | 1,584 |
| EPS (₹) | -6.86 | -11.93 | -10.55 | 47.86 | 48.81 |
TTM is the trailing twelve months to the most recent quarter.
Sun Pharma Advanced Research Company Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 99%
- TTM
- 2856%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 108%
- TTM
- 635%
- 10 Years
- -6%
- 5 Years
- -8%
- 3 Years
- -4%
- 1 Year
- 35%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 279%
Sun Pharma Advanced Research Company Ltd shareholding pattern
Promoters held 65.68% at Jun 2026, broadly unchanged since Jun 2025. FIIs 3.90% and DIIs 0.09%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 65.68% | 65.68% | 65.68% | 65.67% | 65.67% | 65.67% | 65.67% | 65.68% |
| FIIs | 2.15% | 2.23% | 1.45% | 1.47% | 1.76% | 2.04% | 2.04% | 3.90% |
| DIIs | 0.21% | 0.64% | 1.13% | 0.97% | 1.05% | 0.78% | 0.88% | 0.09% |
| Public | 31.96% | 31.47% | 31.76% | 31.88% | 31.52% | 31.51% | 31.41% | 30.34% |
| No. of shareholders | 1,28,205 | 1,31,034 | 1,42,864 | 1,40,724 | 1,36,997 | 1,44,810 | 1,40,625 | 1,41,957 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Sun Pharma Advanced Research Company Ltd corporate filings
- Filing of Application for Reclassification with Stock ExchangesCompany Updatelow impact
Cruxal's analysis: Sun Pharma Advanced Research Company Ltd has submitted an application to the stock…
Read the full analysis - Newspaper Advertisement for Publication of FinancialsCompany Updatelow impact
Cruxal's analysis: The company has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Outcome of 21st Annual General Meeting of Sun Pharma Advanced Research Company Limited held on August 10, 2026AGM/EGMhigh impact
Cruxal's analysis: Sun Pharma Advanced Research Company (SPARC) has successfully monetized a Paediatric Rare…
Read the full analysis - Monitoring Agency Report for the Quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: The company has filed its Monitoring Agency Report for the quarter ended June 30, 2026…
Read the full analysis - Outcome of the Board MeetingBoard Meetingmedium impact
Cruxal's analysis: Sun Pharma Advanced Research Company Limited reported a net loss of 20.78 crore for the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Sun Pharma Advanced Research Company Ltd
Cruxal reads every Sun Pharma Advanced Research Company Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.